A systematic literature review of clinical evidence and treatment burden in newly diagnosed high‐risk pediatric patients with classical Hodgkin lymphoma
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.31027 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Jamie E Flerlage und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Hematology and Oncology, University of Rochester Medical Center, Rochester, New York, USA. Hauptthemen laut MEDLINE: Hodgkin Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Pfizer Inc., Pfizer.
Abstract (Originalsprache)
This systematic literature review evaluated frontline treatment burden in pediatric and adolescent/young adult (AYA) patients with high‐risk classical Hodgkin lymphoma (cHL) among studies originating from the United States. Data were extracted from 32 publications (screened: total, n = 3115; full‐text, n = 98) representing 12 studies (randomized controlled trials [RCTs], n = 2; non‐comparative, non‐randomized, n = 7; observational, n = 3). High‐risk disease definitions varied across studies. Five‐year event‐free survival (EFS)/progression‐free survival (PFS) was 86%–100% and 79%–94%, and complete response rates were 35%–100% and 5%–64% for brentuximab vedotin (BV)‐containing and chemotherapy‐alone regimens, respectively. In identified RCTs, BV‐containing compared with chemotherapy‐alone regimens demonstrated significantly longer 3‐year EFS/5‐year PFS. Hematological and peripheral neuropathy were the most commonly reported adverse events of interest, although safety data were inconsistently reported. Few studies evaluated humanistic and no studies evaluated economic burden. Results from studies with the highest quality of evidence indicate an EFS/PFS benefit for frontline BV‐containing versus chemotherapy‐alone regimens for pediatric/AYA patients with high‐risk cHL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Hematology and Oncology, University of Rochester Medical Center, Rochester, New York, USA.
- Maple Health Group, LLC, New York, New York, USA.
- Pfizer Inc., Bothell, Washington, USA.
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
ORCID-Profile: Nicholas Liu
Förderung
- Pfizer Inc.
- Pfizer
Zitieren
APA
Flerlage, J. E., Waters-Banker, C., Fanale, M., Beckerman, R., Castellino, S. M., & Liu, N. (2024). A systematic literature review of clinical evidence and treatment burden in newly diagnosed high‐risk pediatric patients with classical Hodgkin lymphoma. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31027
Vancouver
Flerlage JE, Waters-Banker C, Fanale M, Beckerman R, Castellino SM, Liu N. A systematic literature review of clinical evidence and treatment burden in newly diagnosed high‐risk pediatric patients with classical Hodgkin lymphoma. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31027
BibTeX
@article{Flerlage2024,
author = {Flerlage, Jamie E and Waters-Banker, Christine and Fanale, Michelle and Beckerman, Rachel and Castellino, Sharon M and Liu, Nicholas},
title = {A systematic literature review of clinical evidence and treatment burden in newly diagnosed high‐risk pediatric patients with classical Hodgkin lymphoma},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.31027}
}
EUVIMED